Antitumor activity of PAbs generated by immunization with a novel HER3-targeting protein-based vaccine candidate in preclinical models

被引:1
作者
Bermudez-Abreut, Ernesto [1 ]
Baez, Gretchen Bergado [1 ]
Pestano, Melissa Martinez [1 ]
Attanasio, Giuseppe [2 ]
Castillo, Carlos Yordan Gonzales [1 ]
Fernandez, Diana Rosa Hernandez [1 ]
Alvarez-Arzola, Rydell [1 ]
Alimonti, Andrea [2 ,3 ,4 ,5 ]
Sanchez-Ramirez, Belinda [1 ]
机构
[1] Ctr Mol Immunol CIM, Immunol & Immunotherapy Div, Havana, Cuba
[2] Inst Oncol Res IOR, Dept Mol Oncol, Bellinzona, Switzerland
[3] Univ Svizzera Italiana, Fac Med, Lugano, Switzerland
[4] Univ Padua, Dept Med, Padua, Italy
[5] Oncol Inst Southern Switzerland, Med Oncol, Bellinzona, Switzerland
来源
FRONTIERS IN ONCOLOGY | 2024年 / 14卷
关键词
HER3; ErbB3; immunotherapy; cancer vaccines; PAbs; antitumor effect; CANCER; EGFR; HER3; INACTIVATION; EXPRESSION; APOPTOSIS; SURVIVAL; C-ERBB-3; RECEPTOR; GROWTH;
D O I
10.3389/fonc.2024.1472607
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Despite the cumulative evidence supporting HER3 as a target for antitumor therapies, no agents targeting HER3 have been approved for cancer treatment. Most of the agents evaluated in preclinical and clinical trials have been specific monoclonal antibodies (MAbs), with few examples of active immunotherapy directed against this receptor. However, some cancer vaccine formats may generate polyclonal antibodies (PAbs) that replicate the diverse effector mechanisms of MAbs, including ligand neutralization and receptor degradation. In this study, we developed a protein subunit-based monovalent vaccine candidate targeting the extracellular domain (ECD) of HER3. Immunization of mice with a formulation targeting murine ErbB3-ECD successfully overcome tolerance to this self-antigen, inducing high titers of ErbB3-specific PAbs. The antitumor potential of this formulation and the induced PAbs was demonstrated in vivo and in vitro in an ErbB3-overexpressing 3LL-D122-derived tumor model. The immunogenicity of the HER3-ECD-based vaccine candidate was confirmed by the induction of high titers of HER3-specific PAbs. Consistent with the initial results, HER3-ECD-targeting PAbs were cytotoxic in several human epithelial tumor cell lines and exerted antitumor effects in vivo. These results support the value of HER3 as a tumor antigen and the effector mechanisms of HER3-specific therapeutic MAbs, while suggesting the potential of the proposed vaccine candidate for the treatment of HER3-expressing carcinomas.
引用
收藏
页数:14
相关论文
共 47 条
  • [1] HER1-ECD vaccination dispenses with emulsification to elicit HER1-specific anti-proliferative effects
    Aguiar Alpizar, Yeranddy
    Sanchez Ramirez, Belinda
    Hernandez Fernadez, Diana Rosa
    Rabasa Capote, Ailem
    Garrido Hidalgo, Greta
    Perez Rodriguez, Rolando
    Fernandez Molina, Luis Enrique
    [J]. HUMAN VACCINES, 2009, 5 (03): : 158 - 165
  • [2] Amin DN., 2010, SEMINARS CELL DEV BI
  • [3] Bergado-Baez G., 2022, Polyclonal antibody-induced downregulation of HER1/EGFR and HER2 surpasses the effect of combinations of specific registered antibodies, V12, DOI [10.3389/fonc.2022.951267, DOI 10.3389/FONC.2022.951267]
  • [4] Inhibition of doxorubicin-induced HER3-PI3K-AKT signalling enhances apoptosis of ovarian cancer cells
    Bezler, Martin
    Hengstler, Jan G.
    Ullrich, Axel
    [J]. MOLECULAR ONCOLOGY, 2012, 6 (05) : 516 - 529
  • [5] Caballero I., 2017, Safety and immunogenicity of a human epidermal growth factor receptor 1 (HER1)-based vaccine in prostate castration-resistant carcinoma patients: a dose-escalation phase I study trial, V8, P263, DOI [10.3389/fphar.2017.00263, DOI 10.3389/FPHAR.2017.00263]
  • [6] Campbell MR., 2010, HER3 comes of age: new insights into its functions and role in signaling, tumor biology, and cancer therapy, V16, P1373, DOI [10.1158/1078-0432.CCR-09-1218, DOI 10.1158/1078-0432.CCR-09-1218]
  • [7] Chen L., 2011, Dual EGFR/HER2 inhibition sensitizes prostate cancer cells to androgen withdrawal by suppressing ErbB3, V17, P6218, DOI [10.1158/1078-0432.CCR-11-1548, DOI 10.1158/1078-0432.CCR-11-1548]
  • [8] Cleary KL., 2017, Antibody distance from the cell membrane regulates antibody effector mechanisms, V198, P3999, DOI [10.4049/jimmunol.1601473, DOI 10.4049/JIMMUNOL.1601473]
  • [9] Engelman JA., 2007, MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling, V316, P1039, DOI DOI 10.1126/SCIENCE.1141478
  • [10] Cancer vaccines: Between the idea and the reality
    Finn, OJ
    [J]. NATURE REVIEWS IMMUNOLOGY, 2003, 3 (08) : 630 - 641